Crossmark

LPE-1, an orally active pyrimidine derivative, inhibits growth and mobility of human esophageal cancers by targeting LSD1

Crossref DOI link: https://doi.org/10.1016/j.phrs.2017.05.025

Published Print: 2017-08

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Wang, Bo

Zhao, Bing

Pang, Lu-Ping

Zhao, Yuan-Di

Guo, Qian

Wang, Jun-Wei

Zheng, Yi-Chao

Zhang, Xin-Hui

Liu, Ying

Liu, Guang-Yao

Guo, Wen-Ge

Wang, Chao

Li, Zhong-Hua

Mao, Xue-Jing

Yu, Bin

Ma, Li-Ying

Liu, Hong-Min
Funding

Funding for this research was provided by:

Natural Science Foundation of China (21372206, 81430085)

Development Foundation of Priority, Ministry of Education (20134101130001)

National Key Research Programs of Proteins (2016YFA0501800)

Key Research Program of Henan Province (161100310100)

Starting Grant of Zhengzhou University (32210533)
License Information

Text and Data Mining valid from 2017-08-01
More Information

This article is maintained by: Elsevier

Article Title: LPE-1, an orally active pyrimidine derivative, inhibits growth and mobility of human esophageal cancers by targeting LSD1

Journal Title: Pharmacological Research

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.phrs.2017.05.025

Content Type: article

Copyright: © 2017 Elsevier Ltd. All rights reserved.